Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Antifreeze Proteins Block Growth of Ice Crystals by Binding Irreversibly

By BiotechDaily International staff writers
Posted on 28 Feb 2013
Antifreeze proteins (AFPs) bind irreversibly to ice crystals and prevent their growth even when no more protein is left in solution.

AFPs create a difference between the melting point and freezing point known as thermal hysteresis. The addition of AFPs at the interface between solid ice and liquid water inhibits the thermodynamically favored growth of the ice crystal, while ice growth is kinetically inhibited by the AFPs covering the water-accessible surfaces of the ice. Thermal hysteresis is easily measured in the lab with an instrument called a nanoliter osmometer.

Many organisms are protected from freezing by AFPs, which bind to ice, modify its morphology, and prevent its further growth. Since the initial discovery of AFPs in fish, they have also been found in insects, plants, bacteria, and fungi. These proteins have a wide range of applications in cryomedicine, cryopreservation, and frost protection for transgenic plants and vegetables. AFPs also serve as a model for understanding biomineralization, the processes by which proteins help form bones, teeth, and shells. Nonetheless, the mechanism of action of different types of antifreeze proteins is incompletely understood. Antifreeze proteins evolved independently many times with diverse structures and properties, even in closely related species. Although AFPs were discovered more than 30 years ago and have been studied extensively since then, it is not clear whether all AFPs block ice growth through a unified mechanism of action or if these diverse proteins have distinct binding properties. As measurements of the antifreeze proteins in contact with ice were elusive, this question had not been answered.

To elucidate some of these issues investigators at the Hebrew University of Jerusalem (Israel) and Ohio University (Athens, USA) prepared a fluorescently labeled version of the yellow mealworm (Tenebrio molitor) AFP. This protein is a hyperactive AFP with potency to arrest ice growth hundreds of times greater than that of fish or plant AFPs. Use of the labeled protein allowed for direct microscopic observation of protein-ice crystal interaction in a custom-designed, temperature-controlled microfluidic device.

Results published in the January 8, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed that the binding of hyperactive Tenebrio molitor AFP to ice crystals was practically irreversible, and that surface-bound AFPs were sufficient to inhibit ice crystal growth even in solutions depleted of AFPs. These findings ruled out theories of AFP activity relying on the presence of unbound protein molecules.

Related Links:
Hebrew University of Jerusalem
Ohio University


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.